These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11533610

  • 1. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
    Porter KE, Dickinson T, London NJ.
    J Vasc Surg; 2001 Sep; 34(3):548-54. PubMed ID: 11533610
    [Abstract] [Full Text] [Related]

  • 2. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ, Beil ME, Bruseo CW, Fink CA, Hoyer D, Savage P, Jeng AY.
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [Abstract] [Full Text] [Related]

  • 3. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V, Martinez-Miguel P, Arribas-Gomez I, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S.
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [Abstract] [Full Text] [Related]

  • 4. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME.
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [Abstract] [Full Text] [Related]

  • 5. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M.
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [Abstract] [Full Text] [Related]

  • 6. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
    Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP.
    Life Sci; 2012 Oct 15; 91(13-14):743-8. PubMed ID: 22480515
    [Abstract] [Full Text] [Related]

  • 7. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY.
    Life Sci; 2000 Oct 15; 67(9):1025-33. PubMed ID: 10954036
    [Abstract] [Full Text] [Related]

  • 8. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle.
    Maguire JJ, Johnson CM, Mockridge JW, Davenport AP.
    Br J Pharmacol; 1997 Dec 15; 122(8):1647-54. PubMed ID: 9422810
    [Abstract] [Full Text] [Related]

  • 9. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Jeng AY, Savage P, Beil ME, Bruseo CW, Hoyer D, Fink CA, Trapani AJ.
    Clin Sci (Lond); 2002 Aug 15; 103 Suppl 48():98S-101S. PubMed ID: 12193064
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM, Moliterni JA, Moskal MA, Neubert AD, Marcopulos N, Stamford LB, Trapani AJ, Savage P, Chou M, Jeng AY.
    J Med Chem; 1998 Apr 23; 41(9):1513-23. PubMed ID: 9554884
    [Abstract] [Full Text] [Related]

  • 11. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA, Schirger JA, Wennberg PW, Sandberg S, Heublein DM, Subkowski T, Burnett JC.
    Circulation; 2000 Apr 25; 101(16):1976-81. PubMed ID: 10779465
    [Abstract] [Full Text] [Related]

  • 12. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
    Kukkola PJ, Savage P, Sakane Y, Berry JC, Bilci NA, Ghai RD, Jeng AY.
    J Cardiovasc Pharmacol; 1995 Apr 25; 26 Suppl 3():S65-8. PubMed ID: 8587470
    [Abstract] [Full Text] [Related]

  • 13. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM, Savage P, Trapani AJ, Balwierczak JL, Jeng AY.
    J Cardiovasc Pharmacol; 1998 Apr 25; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [Abstract] [Full Text] [Related]

  • 14. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
    Usmani BA, Harden B, Maitland NJ, Turner AJ.
    Clin Sci (Lond); 2002 Aug 25; 103 Suppl 48():314S-317S. PubMed ID: 12193112
    [Abstract] [Full Text] [Related]

  • 15. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL, Winardi W, Jeng AY, Kwan AL.
    Neurol Res; 2006 Oct 25; 28(7):721-9. PubMed ID: 17164035
    [Abstract] [Full Text] [Related]

  • 16. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice.
    De Campo BA, Goldie RG, Jeng AY, Henry PJ.
    Clin Sci (Lond); 2002 Aug 25; 103 Suppl 48():353S-356S. PubMed ID: 12193121
    [Abstract] [Full Text] [Related]

  • 17. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, Fitt J, Hoyer D, Simonsbergen D, Moliterni J, Marcopoulos N, Savage P, Chou M, Trapani AJ, Jeng AY.
    J Med Chem; 2000 Feb 10; 43(3):488-504. PubMed ID: 10669576
    [Abstract] [Full Text] [Related]

  • 18. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
    Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C.
    J Cardiovasc Pharmacol; 2004 Apr 10; 43(4):489-94. PubMed ID: 15085059
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B, Daull P, Jeng AY.
    Cardiovasc Drug Rev; 2005 Apr 10; 23(4):317-30. PubMed ID: 16614731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.